Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Liposomal Eribulin Mesylate

Known as: E7389 Liposomal Formulation, E7389-LF 
A liposome-encapsulated formulation of the mesylate salt form of eribulin, a synthetic, macrocyclic ketone analogue of halichondrin B, a substance… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Abstract Background Eribulin is approved for treatment of advanced/metastatic breast cancer and previously treated, unresected… Expand
2015
2015
E7389 (eribulin mesylate, Halaven, Eisai) is a fully synthetic analog of the marine sponge natural product halichondrin B. It has… Expand
Review
2015
Review
2015
Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 3
2013
2013
Eribulin mesylate (E7389), a tubulin and microtubule inhibitor, has been approved to treat metastatic breast cancer in certain… Expand
Highly Cited
2009
Highly Cited
2009
With sequential use of catalytic asymmetric Cr-mediated coupling reactions, E7389 C14-C35 and halichondrin C14-C38 building… Expand
  • figure 1
2009
2009
Cr-mediated coupling reactions are usually achieved with a slight excess of a given nucleophile. To develop a cost-effective use… Expand
2009
2009
A practical method is reported to synthesize E7389 C27-C35 building block 13 from 1,2-O-isopropylidene-alpha-D-5-deoxyglucurono-6… Expand
  • figure 1
  • figure 2
2007
2007
The American Cancer Society projected that, in 2006, more than 212,000 cases of invasive breast cancer would be diagnosed and… Expand